About Relugolix API
Therapeutic CategoryAnti-Cancer/ Oncology-es
CAS Number
737789-87-6
API Technology
Synthetic
Dose Form
Oral Solid/Tablets, Injectable
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF
Mechanism of Action
Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.
Indication
ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Related APIs
Acalabrutinib
Anti-Cancer/ Oncology-es
Enzalutamide-es
Anti-Cancer/ Oncology-es
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!